Quick Answer
Solid Biosciences Inc. reported R&D Expense of $140.32 million for fiscal year 2025.
Solid Biosciences Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $140.32M | +45.5% |
| 2024 | $96.43M | +25.9% |
| 2023 | $76.56M | -2.4% |
| 2022 | $78.42M | +33.5% |
| 2021 | $58.74M | -9.5% |
| 2020 | $64.88M | -31.5% |
| 2019 | $94.74M | +63.4% |
| 2018 | $57.97M | +45.3% |
| 2017 | $39.91M | +98.4% |
| 2016 | $20.12M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $38.86M | +42.2% | +19.9% |
| June 30, 2025 | $32.41M | +66.6% | +4.9% |
| March 31, 2025 | $30.91M | +63.8% | +13.1% |
| September 30, 2024 | $27.33M | +63.6% | +40.4% |
| June 30, 2024 | $19.46M | -1.6% | +3.1% |
| March 31, 2024 | $18.87M | -23.4% | +13.0% |
| September 30, 2023 | $16.70M | +19.3% | -15.5% |
| June 30, 2023 | $19.78M | -14.7% | -19.7% |
- Solid Biosciences Inc. showed an increase of +45.5% in R&D Expense compared to the prior fiscal year.
- Over the 2016–2025 period, Solid Biosciences Inc.’s r&d expense has grown by 597.6% (from $20.12 million to $140.32 million).
- The most recent figure is from Solid Biosciences Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: